Regulation of proliferation and viability of tumor cells in vitro by alloferon-1 and allostatin-1

Tsitologiya

Volumn 53, Issue 3, 2011, Pages 250-258

  Pleskach, V A ^a   Kozhucharova, I V ^a   Alekseenko, L L ^a   Pleskach, N M ^a   Anikin, V B ^b   Chernysh, S I ^c  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

^b Institute of Influenza RAMS   (United States)

^c ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

Author keywords

Cell line; Clonogenicity; Fluorescence; Growth modulating effect; Peptide; Proliferative activity

Indexed keywords

ALLOFERON; ALLOSTATIN 1; ALLOSTATIN-1; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; OLIGOPEPTIDE; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; CULTURE TECHNIQUE; DRUG EFFECT; FLY; HEMOLYMPH; HUMAN; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; MOUSE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOSTATIC AGENTS; DIPTERA; HEMOLYMPH; HUMANS; MICE; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PEPTIDES;

EID: 79960685974     PISSN: 00413771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Baker M. A., Malay W. L., Zasloff M., Jacob L. S. 1993. Anticancer efficacy of magainin 2 and analogue peptides. Cancer Res. 53: 3052-3057.
6. Bowman H. G. 1995. Peptide antibiotics and their role in innate immunity. Ann. Rev. Immunol. 13: 61-92.
7. Capello A., Krenning E. P., Bernard B. F., Breeman W. A. P., Erion J. L., de Jong M. 2006. Anticancer activity of targeted proapoptotic peptides. J. Nucl. Med. 4: 122-129.
8. Chen H. M., Wang W., Smith D., Chan S. C. 1997. Effects of the antibacterial peptide cecropin B and its analogs cecropin B-1 and B-2 on lysosomes, bacteria and cancer cells. Biochim. biophys. acta. 1336: 171-179.
9. Chernysh S., Kim S. I., Bekker G., Pleskach V. A., Filatova N. A., Anikin V. B., Platonov V. G., Bullet P. 2002. Antiviral and antitumor peptides from insects. Proc. Nat. Acad. Sci. USA. 99: 12 628-12 632.
10. Cwiral S. E., Balasubramanian P., Duffen D. J., Wagstrom C. R., Gates C.M., Singer S. C., Davis A. M., Tansik R. L., Matthtakis L. C., Boytas C. M., Schatz P. J., Paccanar D. P., Wrighton N. C., Barret R. W., Dower R. W. 1996. Peptide against of the thrombopoietin receptor of potent as the natural cytokine. Science. 276: 1696-1699.
11. Dawson D. W., Volpert O. V., Pearce F. A., Schneider A. J., Silverstein A. J., Henkin J., Bouck N. J. 1999. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a trombospondin-1 type 1 repeat. Mol. Phamacol. 2: 332-338.
12. Day F. H., Zhang Yu., Clair P., Grobstein K. H., Mazel M., Rees A. R., Kaczorek M., Temsamani J. 2003. Induction of antigen-specific CTL responses using antigens conujgated to short peptide vectors. J. Immunol. 170: 1498-1503.
13. Delano W. L., Ultsch M. Y., de Vos A. M., Wells J. A. 2000. Convergent solutions to binding at protein-protein interface. Science. 287: 1279-1283.
14. DeVita V. T., Chu E. 2008. A history of cancer chemotherapy. Cancer Res. 68: 8643-8653.
15. Fujihara S. M., Cleaveland J. S., Grosmaire L. S., Berry K. K., Kennedy K.A., Blake J. J., Lay J., Rankin B. M., Ledbetter J. A., Nadler S. G. 2000. A D-amino acid peptide inhibitor of NF-kB nuclear localization is efficacious in models of inflammatory disease. J. Immunol. 185: 1004-1012.
16. 2I ligands: peptide endocytosis and reduction within APS influence T cell recognition. J. Immunol. 166: 4543-4551.
17. Hyde-De Ruyscher R., Paige L. A., Cristensen D. J., Hyde-De Ruyscher N., Lim A., Fredericks Z. L., Kranz J., Gallant P., Zhang J., Rocklage S. M., Fowlkes D. M., Wendler P. A., Hamilton P. T. 1999. Detection of small-molecule enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries. Chem. Biol. 7: 17-25.
18. Johnstone S. A., Gelman K., Mayer L. D., Hancock R. E., Bally M. 2000. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild type and p-glycoprotein overexpressing tumor cell lines. Anti-cancer Drug Design. 15: 151-160.
19. Joliot A., Prochiantz A. 2004. Transduction peptides: from technology to physiology. Nature Cell Biol. 6: 189-196.
20. Kaga H., Okochi M., Nakanishi M., Hayashi H., Kato R., Honda H. 2007. Screening of a novel octamer peptide CNSCWSKD, that induce caspase-dependent cell death. Biochem. Biophys. Res. Commun. 362: 1063-1068.
21. Kay B. K., Kurakin A. V., Hyde-De Ruyscher R. 1998. From peptides to drugs via phage display. Drug Discov. Today. 8: 370-378.
22. Kerkis A., Hayashi M. A. F., Yamane T., Kerkis I. 2008. Properties of cell penetrating peptides (CPPs). Intern. Union Biochem. and Mol. Biol. Life. 58: 7-13.
23. Linn H., Ermekova K. S., Rentschler S., Sparks A. B., Kay B. K., Sudol M. 1997. Using molecular repertories to identify high affinity peptide ligands of theWWdomain of human and mouse YAP. Biol. Chem. 378: 531-537.
24. Livnah O., Stura E. A., Johnson D. L., Mideleton S. A., Mulcaht L. S., Wrighton N. C., Dower W. J., Jolliffe L. K., Wilson I. A. 1996. Functional mimicry of a protein hormone by a peptide against the EPO receptor complex at 2.8 Å. Science. 273: 464-471.
25. Magzoub M., Gräslund A. 2004. Cell-penetrating peptides: small from inception to application. Quart. Rev. Biophys. 37: 147-195.
26. Matsuzaki K., Harada M., Funkoshi S., Fuji N., Miyajimo K. 1991. Physicochemical determinants for the interaction of magainins 1 and 2 with acidic lipid bilayers. Biochim. biophys. acta. 1063: 162-170.
27. Mizejewski G. J., MacColl R. 2003. Alpha-fetoprotein inhibitory peptides potential leads for cancer cherapeutics. Mol. Cancer Ther. 2: 1243-1255.
28. Papo N., Braunstein A., Eshhar Z., Yechiel S. 2004. Supression of human prostate tumor growth in mice by a cytolitic D-, L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res. 64: 5779-5786.
29. Papo N., Shai Y. 2003. New litic peptides based on D, L amphipathic helix motif preferentially kill tumor cells compared with normal cells. Biochemistry. 42: 9346-9354.
30. Rousselle C., Smirnova M., Clair P., Lefauconnier J.-M., Chavanien A., Calos B., Scherrman J.-M., Temsamani J. 2001. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. Pharmacology. 296: 124-131.
31. Russel J. H., Keiler K. C. 2007. Peptide signals encode protein localization. J. Bacteriol. 189: 7581-7585.
32. Sidhu S. S., Weiss G. A. 2002. DNA-encoded peptide libraries and drug discovery. In: Anticancer drug development. London: Acad. Press. 237-248.
33. Waldmann T. A. 2003. Immunotherapy: past, present and future. Nature Med. 9: 269-277.
34. Wang Z., Wang G. 2004. APD: the antimicrobial peptide database. Nucl. Acids Res. 32: D590-D592.
35. Yang D., Biragyn A., Kwak L. W., Oppenheim J. J. 2002. Mammalian definsins in immunity: more than just microbicidal. Trends Immunol. 23: 291-296.